AZD4954 Clinical Trials (2026): 2 Studies for Healthy Participants & Dyslipidemia
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 AZD4954 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Healthy Participants & Dyslipidemia) and 168 total planned enrollment. 2 AZD4954 clinical trials are actively recruiting at 6 U.S. sites across 4 states. Most recent activity: NCT06980428 (Dec 2026).
Where to Participate: All AZD4954 Trial Sites in the U.S. (6 sites across 4 states)
Every actively recruiting AZD4954trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Research Site | Glendale91206 | NCT06980428 | Map |
| CA | Research Site | Glendale91206 | NCT07513571 | Map |
| FL | Research Site | Inverness34452 | NCT06980428 | Map |
| FL | Research Site | Jacksonville32216 | NCT06980428 | Map |
| MD | Research Site | Brooklyn21225 | NCT06980428 | Map |
| TX | Research Site | San Antonio78229 | NCT06980428 | Map |
AZD4954 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 2 | 2 |
Recruiting AZD4954 clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06980428 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia | P1 | Healthy Participants | 136 | May 2025 |
| NCT07513571 | A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults | P1 | Healthy Participants | 32 | Apr 2026 |
All AZD4954 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06980428 | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia | P1 | recruiting | 136 | AstraZeneca | May 2025 | |
| NCT07513571 | A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults | P1 | recruiting | 32 | AstraZeneca | Apr 2026 |
AZD4954 clinical trials: frequently asked questions
- How many AZD4954 clinical trials are there?
- 2 AZD4954 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are AZD4954 clinical trials recruiting in 2026?
- Yes — 2 AZD4954 trials are actively recruiting in 2026, with 6 U.S. sites across 4 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is AZD4954 being studied for?
- AZD4954 is being studied for Healthy Participants, Dyslipidemia. The trials are grouped by indication on this page.
- What phase is AZD4954 in?
- AZD4954 clinical trials span 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors AZD4954 clinical trials?
- The lead sponsor across the most AZD4954 trials is AstraZeneca. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming AZD4954as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: